Valorum Biologics Partners with Formycon for FYB203 in North America

Valorum Biologics LLC has secured an exclusive commercialization agreement with Klinge Biopharma GmbH, owner of Formycon's Eylea® biosimilar, FYB203/AHZANTIVE® (aflibercept-mrbb), for the U.S. and Canada. This partnership marks a significant step for the biosimilar's market entry, facilitated by upfront and milestone payments to Klinge, along with royalties on net sales. Formycon will manage the supply chain and benefit from additional service payments.

Valorum, recognized for its expertise in the U.S. biosimilars market, aims to maximize FYB203's commercial potential. The drug, approved by the FDA for treating retinal diseases, awaits Canada's regulatory approval. Broad market access could alleviate healthcare costs and improve treatment affordability.